Search

Displaying results 611 - 620 of 7554 in total
  1. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    It was first approved by the FDA in 2017. … [A180478] Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.

  2. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].

  3. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. … Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil.

  4. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated

  5. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    [T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

  7. Drug

    Fludeoxyglucose (18F)

    go.drugbank.com/drugs/DB09502
    ApprovedInvestigational

    It is administered by intravenous injection. … Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with

  8. Drug

    Butylscopolamine

    go.drugbank.com/drugs/DB09300
    ApprovedInvestigationalVet approved

    It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms.

    Mixtures: BIPASMIN COMPUESTO N, BIPASMIN COMPUESTO NSynonyms: N-butylscopolammonium, N-butylscopolammonium ion
  9. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

  10. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Mixtures: Vamin N, OLIMEL N9-840 İNFÜZYONLUK AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML